SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

June 11, 2013 09:00 ET

Therapeutic Solutions International, Inc. Announces Formation of Scientific Advisory Board

Dr. Barry Glassman Appointed as Chairman

OCEANSIDE, CA--(Marketwired - Jun 11, 2013) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the creation of a Scientific Advisory Board with Dr. Barry Glassman appointed as Chairman.

Dr. Glassman, Vice President of Education and Training for TSI, said, "Our goal is to attract both clinical and research oriented professionals to guide product development and utilization. This Advisory Board will serve to continue our efforts to use evidenced based concepts in the advancement of the use of already proven therapy. This will help guide our efforts to educate more health practitioners, thereby increasing the use of appliance therapy in general dentistry, the treatment of trigeminally mediated disorders, as well as the treatment of sleep disturbed breathing."

Tim Dixon, CEO of TSI, stated, "The new Scientific Advisory Board will allow TSI management to tap into the expertise of additional appointees that Dr. Glassman brings to this Board to consider additional technologies and products that fit within our mission statement to provide cost effective treatment modalities and products."

Therapeutic Solutions International is the global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today.

About Therapeutic Solutions International, Inc.

The Company's corporate website is Non-US dentists and physicians can order our AMPSA products at

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information

  • For more information please contact:

    Therapeutic Solutions International, Inc.